What is the role of rituximab in the treatment of peripheral ulcerative keratitis (PUK)?

Updated: Jun 11, 2019
  • Author: Ellen N Yu-Keh, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print
Answer

Rituximab, a chimeric monoclonal antibody directed against the CD20 protein found in B cells, has been used in treatment-resistant PUK in GPA [40] and RA [41] , and was noted to have the highest success rate in achieving steroid-free remission in GPA-associated PUK. [42]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!